Your Health, We Care
On March 22, 2024, the U.S. FDA approved expanded broad indication labeling for Nexletol and Nexlizet for the prevention of heart attacks and cardiovascular interventions in patients for primary and secondary prevention, regardless of statin use.
On December 13, 2023, the U.S. FDA updated the low-density lipoprotein cholesterol (LDL‑C) lowering indications for Esperion Therapeutics' Nexletol (bempedoic acid) tablets and Nexlizet (bempedoic acid/ezetimibe) tablets.
On February 21, 2020, the FDA approved Nexletol (bempedoic acid) for the reduction of low-density lipoprotein cholesterol.
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
